wow script tracker...very stalble nilandron up 40 % Script Tracker - Week Ended Oct 7th Our view: Given recent U.S. product and pricing volatility, we believe it is important to provide investors with a weekly in-depth view of script trends. Our forecasts do not reflect completion of the $350MM senior note offering. Key points: Plaquenil AG TRx down 1.2% WoW, slightly underperforms broader market. Plaquenil AG (Prasco) TRx were down 1.2% WoW vs. up 1.2% the prior week. Total hydroxychloroquine (broader plaquenil market) TRxs were down 0.1% WoW and Prasco's market share (Concordia AG) currently sits at 38.2% of TRx vs. 38.6% the prior week. We have outlined Plaquenil/ hydroxychloroquine market share trends in Exhibit 2. As previously noted, we believe Plaquenil AG pricing has decreased by ~40% recently and we note that Concordia confirmed that Plaquenil AG is seeing further pricing pressure due to the Actavis generic (1.9% market share).
Lanoxin AG TRx up 2.1% WoW. Par's (AG) market share was down slightly to 31.2% from 31.5%, Sun Pharma's market share increased from 9.4% to 10.0% this week, WestWard Pharma's share decreased from 9.9% to 9.8%, Digoxin saw its share decrease from 24.9% to 24.8%, and Impax's share was flat at 23.2%. The Lanoxin AG (Par Pharma) saw TRx increase 2.1% WoW vs. a 3.7% increase last week. The broader market saw TRx increase 3.0% WoW. We have outlined Lanoxin/Digoxin market trends in Exhibit 3.
Donnatal TRx down 0.2% WoW. As previously noted, we have been monitoring the market share of several IBS drugs that target both IBS-C and IBS-D, due to the launch of Allergan's Viberzi in December (TRx down 8.1% WoW). While Donnatal saw a slow decline in scripts between January and August, we believe scripts are beginning to stabilize. Donnatal NRx were down 0.6% WoW vs. down 1.8% prior week and TRx were down 0.2% WoW vs. down 0.1% the prior week. Donnatal's current market share (TRx) is 1.7%; Xifaxan holds a 16.1% market share, Viberzi has a 3.9% share, Amitiza has a 27.5% share, and Linzess has a 50.6% share. Exhibit 5 shows Donnatal weekly NRx and TRx trends.
Other CXRX products: Nilandron TRx up 40.0% WoW, Dibenzyline AG TRx up 40.9% WoW, and Kapvay TRx up 0.6% WoW. Nilandron saw TRx of 35, up 40.0% WoW. We note that ANI Pharmaceuticals had a generic version of Nilandron approved by the FDA on July 18. The ANI generic saw TRx increase 76.9% WoW to 46 TRxs. We anticipate that CXRX will launch an AG in the coming weeks.